TD Cowen analyst Dan Brennan raised the firm’s price target on Guardant Health (GH) to $56 from $42 and keeps a Buy rating on the shares. The firm said results were inline with the preannouncement with good 2025 guidance as borad-based momentum continues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $59 from $39 at Raymond James
- Guardant Health price target raised to $60 from $55 at BTIG
- Guardant Health price target raised to $56 from $49 at Guggenheim
- Guardant Health’s Promising Growth Prospects: Buy Rating Backed by Strong Revenue Guidance and Optimistic Projections
- Guardant Health’s Strong 2024 Growth and 2025 Outlook